Chemical mediators of migraine: Preclinical and clinical observations

Headache

Volumn 51, Issue 6, 2011, Pages 1029-1045

  Gupta, Saurabh ^a   Nahas, Stephanie J ^b   Peterlin, B Lee ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

5 HT; CGRP; histamine; migraine; NO

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ALNIDITAN; AVITRIPTAN; BIOLOGICAL MARKER; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CAPSAICIN; DIHYDROERGOTAMINE; ELETRIPTAN; GLUTAMIC ACID; HISTAMINE; HISTAMINE H3 RECEPTOR; LASMIDITAN; MESSENGER RNA; N METHYLHISTAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OLCEGEPANT; PROTEIN C FOS; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; TELCAGEPANT; VALPROATE SEMISODIUM; ZOLMITRIPTAN;

ANALGESIA; BIOAVAILABILITY; BLOOD BRAIN BARRIER; CHRONIC DAILY HEADACHE; CHRONIC FATIGUE SYNDROME; DISEASE MARKER; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; MENINGEAL ARTERY; MIDDLE CEREBRAL ARTERY; MIGRAINE; NERVE POTENTIAL; NEUROGENIC INFLAMMATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPERIOR SAGITTAL SINUS; TRIGEMINUS GANGLION; UPPER ABDOMINAL PAIN; VASODILATATION; VENOCONSTRICTION;

BRAIN CHEMISTRY; CALCITONIN GENE-RELATED PEPTIDE; HISTAMINE; HUMANS; MIGRAINE DISORDERS; NITRIC OXIDE; SEROTONIN;

EID: 79958082121     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01929.x     Document Type: Review

References (234)

1. Rapport MM, Green AA, Page IH,. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem. 1948; 176: 1243-1251.
2. Rapport MM,. Serum vasoconstrictor (serotonin) the presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle. J Biol Chem. 1949; 180: 961-969.
3. Villalon CM, Centurion D,. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007; 376: 45-63.
4. Peterlin BL, Rapoport AM,. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin Drug Metab Toxicol. 2007; 4: 899-911. (Pubitemid 350285342)
5. Hannon J, Hoyer D,. Molecular biology of 5-HT receptors. Behav Brain Res. 2008; 195: 198-213.
6. Hoyer D, Clarke DE, Fozard JR, et al,. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994; 46: 157-203. (Pubitemid 24185150)
7. Ferrari MD, Wilkinson M, Hirt D, Lataste X, Notter M,. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group. Pain. 1991; 45: 283-291.
8. Workman EA, Tellian F, Short D,. Trazodone induction of migraine headache through mCPP. Am J Psychiatry. 1992; 149: 712.
9. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E,. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol. 1996; 50: 219-223. (Pubitemid 26265123)
10. Bouchelet I, Case B, Olivier A, Hamel E,. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: Similarity with human coronary artery. Br J Pharmacol. 2000; 129: 501-508. (Pubitemid 30083871)
11. Bonaventure P, Langlois X, Leysen JE,. Co-localization of 5-HT1B- and 5-HT1D receptor mRNA in serotonergic cell bodies in guinea pig dorsal raphé nucleus: A double labeling in situ hybridization histochemistry study. Neurosci Lett. 1998; 254: 113-116. (Pubitemid 28454845)
12. Rebeck GW, Maynard KI, Hyman BT, Moskowitz MA,. Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc Natl Acad Sci U S A. 1994; 91: 3666-3669.
13. Bruinvels AT, Landwehrmeyer B, Gustafson EL, et al,. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 1994; 33: 367-386.
14. Waeber C, Moskowitz MA,. [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: An autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol. 1995; 352: 263-275.
15. Muller-Schweinitzer E, Weidmann H,. Regional differences in the responsiveness of isolated arteries from cattle, dog and man. Agents Actions. 1977; 7: 383-389. (Pubitemid 8183979)
16. Owman C, Edvinsson L, Hardebo JE,. Pharmacological in vitro analysis of amine-mediated vasomotor functions in the intracranial and extracranial vascular beds. Blood Vessels. 1978; 15: 128-147. (Pubitemid 8285771)
17. Gupta S, Villalon CM,. The relevance of preclinical research models for the development of antimigraine drugs: Focus on 5-HT(1B/1D) and CGRP receptors. Pharmacol Ther. 2010; 128: 170-190.
18. Martin GR, Robertson AD, MacLennan SJ, et al,. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997; 121: 157-164. (Pubitemid 27192699)
19. Cohen ML, Schenck K,. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: Lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999; 290: 935-939. (Pubitemid 29400228)
20. Cohen ML, Schenck K,. Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: Effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br J Pharmacol. 2000; 131: 562-568.
21. Nelson DL, Phebus LA, Johnson KW, et al,. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010; 30: 1159-1169.
22. Saxena PR, De Vries P, Wang W, et al,. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol. 1997; 355: 295-302. (Pubitemid 27065322)
23. MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR,. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology. 2000; 55: 1524-1530.
24. Mueller L, Gallagher RM, Ciervo CA,. Vasospasm-induced myocardial infarction with sumatriptan. Headache. 1996; 36: 329-331. (Pubitemid 26162559)
25. Laine K, Raasakka T, Mantynen J, Saukko P,. Fatal cardiac arrhythmia after oral sumatriptan. Headache. 1999; 39: 511-512. (Pubitemid 29400305)
26. Rowbotham GF, Little E,. New concepts on the aetiology and vascularization of meningiomata; the mechanism of migraine; the chemical processes of the cerebrospinal fluid; and the formation of collections of blood or fluid in the subdural space. Br J Surg. 1965; 52: 21-24.
27. Saxena PR, Verdouw PD,. Tissue blood flow and localization of arteriovenous anastomoses in pigs with microspheres of four different sizes. Pflugers Arch. 1985; 403: 128-135. (Pubitemid 15131526)
28. Den Boer MO, Villalon CM, Heiligers JP, Humphrey PP, Saxena PR,. Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol. 1991; 102: 323-330.
29. De Vries P, Willems EW, Heiligers JP, Villalon CM, Saxena PR,. Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses. Br J Pharmacol. 1999; 127: 405-412. (Pubitemid 29245678)
30. McCall RB,. Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: A novel migraine model. Brain Res. 1997; 775: 189-192. (Pubitemid 28020503)
31. Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ,. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol. 1997; 328: 61-64. (Pubitemid 27241396)
32. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL,. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia. 1997; 17: 525-531. (Pubitemid 27248490)
33. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL,. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia. 1997; 17: 518-524. (Pubitemid 27248489)
34. Cutrer FM, Yu XJ, Ayata G, Moskowitz MA, Waeber C,. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology. 1999; 38: 1043-1053. (Pubitemid 29240621)
35. Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al,. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia. 2001; 21: 727-732. (Pubitemid 34621538)
36. Goadsby PJ, Knight Y,. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors. Br J Pharmacol. 1997; 122: 918-922. (Pubitemid 27460175)
37. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS,. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res. 2002; 953: 181-188. (Pubitemid 35217819)
38. Hoskin KL, Lambert GA, Donaldson C, Zagami AS,. The 5- hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004; 998: 91-99. (Pubitemid 38081286)
39. Bartsch T, Knight YE, Goadsby PJ,. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004; 56: 371-381. (Pubitemid 39166556)
40. Supornsilpchai W, Sanguanrangsirikul S, Maneesri S, Srikiatkhachorn A,. Serotonin depletion, cortical spreading depression, and trigeminal nociception. Headache. 2006; 46: 34-39.
41. Ma QP,. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport. 2001; 12: 1589-1591.
42. Anttila V, Stefansson H, Kallela M, et al,. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010; 42: 869-873.
43. Hoskin KL, Kaube H, Goadsby PJ,. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996; 119: 249-256.
44. Hoskin KL, Kaube H, Goadsby PJ,. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain. 1996; 119 (Pt 5): 1419-1428. (Pubitemid 26375714)
45. Goadsby PJ, Hoskin KL,. Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain. 1999; 82: 15-22. (Pubitemid 29287081)
46. 1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997; 61: 2117-2126. (Pubitemid 27478839)
47. 1F) receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet. 2001; 358: 1230-1234. (Pubitemid 33010848)
48. Ostfeld AM, Chapman LF, Goodell H, Wolff HG,. Studies in headache: A summary of evidence implicating a locally active chemical agent in migraine. Trans Am Neurol Assoc. 1956;(81st Meeting): 35-36.
49. Kimball RW, Friedman AP, Vallejo E,. Effect of serotonin in migraine patients. Neurology. 1960; 10: 07-111.
50. Kimball RW, Friedman AP,. Further studies of neurohumoral agents in patients with vascular headaches. Neurology. 1961; 11: 116-119.
51. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW,. Serotonin metabolism in migraine. Neurology. 1989; 39: 1239-1242. (Pubitemid 19239731)
52. Anthony M, Hinterberger H,. Amine turnover in migraine. Proc Aust Assoc Neurol. 1975; 12: 43-47.
53. Marukawa H, Shimomura T, Takahashi K,. Salivary substance P, 5-hydroxytryptamine, and gamma-aminobutyric acid levels in migraine and tension-type headache. Headache. 1996; 36: 100-104. (Pubitemid 26067608)
54. Kovacs K, Bors L, Tothfalusi L, et al,. Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia. 1989; 9: 53-57.
55. Hegerl U, Juckel G,. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis. Biol Psychiatry. 1993; 33: 173-187. (Pubitemid 23089966)
56. Wang W, Timsit-Berthier M, Schoenen J,. Intensity dependence of auditory evoked potentials is pronounced in migraine: An indication of cortical potentiation and low serotonergic neurotransmission? Neurology. 1996; 46: 1404-1409. (Pubitemid 26159305)
57. Hamel E, Saxena PR,. 5-hydroxtryptamine involvement in migraines. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. Headaches, 3rd edn. Philadelphia, PA: Lippincott Williams and Wilkins; 2006: 275-280.
58. Humphrey PPA, Feniuk W,. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991; 12: 444-446.
59. Schuh-Hofer S, Richter M, Geworski L, et al,. Increased serotonin transporter availability in the brainstem of migraineurs. J Neurol. 2007; 254: 789-796. (Pubitemid 47012461)
60. Doenicke A, Brand J, Perrin VL,. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet. 1988; 1: 1309-1311.
61. Loder E,. Triptan therapy in migraine. N Engl J Med. 2010; 363: 63-70.
62. Bigal ME, Krymchantowski AV, Ho T,. Migraine in the triptan era: Progresses achieved, lessons learned and future developments. Arq Neuropsiquiatr. 2009; 67: 559-569.
63. Ramadan NM, Skljarevski V, Phebus LA, Johnson KW,. 5-HT1F receptor agonists in acute migraine treatment: A hypothesis. Cephalalgia. 2003; 23: 776-785. (Pubitemid 37255418)
64. Leysen JE, Gommeren W, Heylen L, et al,. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: Ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996; 50: 1567-1580.
65. Goldstein J, Dahlof CG, Diener HC, et al,. Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study. Subcutaneous Alniditan Study Group. Cephalalgia. 1996; 16: 497-502. (Pubitemid 26373788)
66. Ferrari MD, Farkkila M, Reuter U, et al,. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178.
67. Granier I, Garcia E, Geissler A, Boespflug MD, Durand-Gasselin J,. Postpartum cerebral angiography associated with the administration of sumatriptan and dihydroergotamine: A case report. Intensive Care Med. 1999; 25: 532-534. (Pubitemid 29240454)
68. Friberg L, Olesen J, Iversen HK, Sperling B,. Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan. Lancet. 1991; 338: 13-17.
69. Thomaides T, Karagounakis D, Spantideas A, Katelanis S,. Transcranial Doppler in migraine attacks before and after treatment with oral zolmitriptan or sumatriptan. Headache. 2003; 43: 54-58. (Pubitemid 36150991)
70. Totaro R, De Matteis G, Marini C, Baldassarre M, Carolei A,. Sumatriptan and cerebral blood flow velocity changes during migraine attacks. Headache. 1997; 37: 635-639. (Pubitemid 28012112)
71. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD,. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain. 2008; 131 (Pt 8): 2192-2200.
72. Asghar MS, Hansen AE, Kapijimpanga T, et al,. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010; 75: 1520-1526.
73. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM,. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982; 298: 240-244. (Pubitemid 12089405)
74. 2 receptor subtypes. Ann N Y Acad Sci. 1992; 657: 88-105.
75. van Rossum D, Hanisch UK, Quirion R,. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997; 21: 649-678. (Pubitemid 27458805)
76. Mulderry PK, Ghatei MA, Spokes RA, et al,. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988; 25: 195-205.
77. McLatchie LM, Fraser NJ, Main MJ, et al,. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393: 333-339. (Pubitemid 28269699)
78. Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R,. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience. 2003; 120: 677-694. (Pubitemid 36928066)
79. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF,. Role of calcitonin gene-related peptide in light-aversive behavior: Implications for migraine. J Neurosci. 2009; 29: 8798-8804.
80. Fiscus RR, Zhou HL, Wang X, et al,. Calcitonin gene-related peptide (CGRP)-induced cyclic AMP, cyclic GMP and vasorelaxant responses in rat thoracic aorta are antagonized by blockers of endothelium-derived relaxant factor (EDRF). Neuropeptides. 1991; 20: 133-143.
81. Fiscus RR, Wang X, Hao H,. hCGRP8-37 antagonizes vasodilations and cAMP responses to rat CGRP in rat caudal artery. Ann N Y Acad Sci. 1992; 657: 513-515.
82. Vause CV, Durham PL,. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem. 2009; 110: 811-821.
83. Liu Y, Broman J, Edvinsson L,. Central projections of the sensory innervation of the rat middle meningeal artery. Brain Res. 2008; 1208: 103-110.
84. Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F,. Calcitonin gene-related peptide (CGRP): Perivascular distribution and vasodilatory effects. Regul Pept. 1986; 15: 1-23. (Pubitemid 16045678)
85. Ebersberger A, Averbeck B, Messlinger K, Reeh PW,. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience. 1999; 89: 901-907. (Pubitemid 29071014)
86. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L,. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999; 76: 176-183. (Pubitemid 29322040)
87. Lennerz JK, Ruhle V, Ceppa EP, et al,. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008; 507: 1277-1299. (Pubitemid 351413572)
88. Kruger L, Mantyh PW, Sternini C, Brecha NC, Mantyh CR,. Calcitonin gene-related peptide (CGRP) in the rat central nervous system: Patterns of immunoreactivity and receptor binding sites. Brain Res. 1988; 463: 223-244.
89. Gulbenkian S, Uddman R, Edvinsson L,. Neuronal messengers in the human cerebral circulation. Peptides. 2001; 22: 995-1007. (Pubitemid 32522976)
90. Conti F, Sternini C,. Calcitonin gene-related peptide (CGRP)-positive neurons and fibers in the cat periaqueductal grey matter. Somatosens Mot Res. 1989; 6: 497-511. (Pubitemid 19270405)
91. Gregg KV, Bishop GA, King JS,. Fine structural analysis of calcitonin gene-related peptide in the mouse inferior olivary complex. J Neurocytol. 1999; 28: 431-438. (Pubitemid 30399506)
92. Goadsby PJ, Edvinsson L,. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56. (Pubitemid 23009909)
93. Edwards RM, Stack EJ, Trizna W,. Calcitonin gene-related peptide stimulates adenylate cyclase and relaxes intracerebral arterioles. J Pharmacol Exp Ther. 1991; 257: 1020-1024.
94. Hanko J, Hardebo JE, Kahrstrom J, Owman C, Sundler F,. Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibres and dilates pial and peripheral arteries. Neuro Sci Ltr. 1985; 57: 91-95. (Pubitemid 15014810)
95. Doods H,. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs. 2001; 2: 1261-1268. (Pubitemid 32878606)
96. Moreno MJ, Abounader R, Hebert E, Doods H, Hamel E,. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: Potential implications in acute migraine treatment. Neuropharmacology. 2002; 42: 568-576. (Pubitemid 34304249)
97. Gupta S, Mehrotra S, Villalon CM, et al,. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: Evidence for CGRP receptor heterogeneity. Eur J Pharmacol. 2006; 530: 107-116. (Pubitemid 43037131)
98. Gupta S, Mehrotra S, Avezaat CJJ, Villalõn CM, Saxena PR, MaassenVanDenBrink A,. Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci. 2006; 79: 265-271. (Pubitemid 43804825)
99. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L,. In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol. 2003; 481: 207-216. (Pubitemid 37464972)
100. Edvinsson L, Nilsson E, Jansen-Olesen I,. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol. 2007; 150: 633-640. (Pubitemid 46355559)
101. Escott KJ, Connor HE, Brain SD, Beattie DT,. The involvement of calcitonin gene-related peptide (CGRP) and substance P in feline pial artery diameter responses evoked by capsaicin. Neuropeptides. 1995; 29: 129-135.
102. Faraci FM, Breese KR,. Dilatation of cerebral arterioles in response to N-methyl-D-aspartate: Role of CGRP and acetylcholine. Brain Res. 1994; 640: 93-97. (Pubitemid 24086534)
103. Busija DW, Chen J,. Effects of trigeminal neurotransmitters on piglet pial arterioles. J Dev Physiol. 1992; 18: 67-72. (Pubitemid 23100578)
104. Goldstein DJ, Offen WW, Klein EG, et al,. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia. 2001; 21: 102-106. (Pubitemid 32575472)
105. Akerman S, Kaube H, Goadsby PJ,. Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol. 2003; 140: 718-724. (Pubitemid 37386436)
106. Gupta S, Bhatt DK, Boni LJ, Olesen J,. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia. 2010; 30: 27-36.
107. Kapoor K, Arulmani U, Heiligers JP, et al,. Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol. 2003; 140: 329-338. (Pubitemid 37249193)
108. Kapoor K, Arulmani U, Heiligers JP, et al,. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Br J Pharmacol. 2003; 475: 69-77. (Pubitemid 37088008)
109. Wahl M, Schilling L, Parsons AA, Kaumann A,. Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res. 1994; 637: 204-210. (Pubitemid 24061049)
110. Colonna DM, Meng W, Deal DD, Busija DW,. Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits. Am J Physiol. 1994; 266 (Pt 2): H1095-H1102.
111. Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ,. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol. 1999; 126: 1478-1486. (Pubitemid 29142080)
112. Levy D, Burstein R, Strassman AM,. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine. Ann Neurol. 2005; 58: 698-705. (Pubitemid 41552545)
113. Fischer MJ, Koulchitsky S, Messlinger K,. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci. 2005; 25: 5877-5883. (Pubitemid 40911418)
114. Koulchitsky S, Fischer MJ, Messlinger K,. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia. 2009; 29: 408-417.
115. Storer RJ, Akerman S, Goadsby PJ,. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004; 142: 1171-1181. (Pubitemid 39093014)
116. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA,. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol. 1995; 116: 3199-3204. (Pubitemid 26007763)
117. Clayton JS, Gaskin PJ, Beattie DT,. Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig. Brain Res. 1997; 775: 74-80. (Pubitemid 28020491)
118. Harada N, Narimatsu N, Kurihara H, Nakagata N, Okajima K,. Stimulation of sensory neurons improves cognitive function by promoting the hippocampal production of insulin-like growth factor-I in mice. Transl Res. 2009; 154: 90-102.
119. Sixt ML, Messlinger K, Fischer MJ,. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain. 2009; 132 (Pt 11): 3134-3141.
120. Knyihar-Csillik E, Tajti J, Samsam M, Sary G, Slezak S, Vecsei L,. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci. 1997; 48: 449-464. (Pubitemid 27240816)
121. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L,. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000; 12: 3991-4002.
122. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF,. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007; 27: 2693-2703. (Pubitemid 46393588)
123. Giniatullin R, Nistri A, Fabbretti E,. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol Neurobiol. 2008; 37: 83-90.
124. Knight YE, Edvinsson L, Goadsby PJ,. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: A comparison of avitriptan and CP122,288. Neuropeptides. 1999; 33: 41-46. (Pubitemid 29248963)
125. Fischer MJ, Messlinger K,. Cannabinoid and vanilloid effects of R(+)-methanandamide in the hemisected meningeal preparation. Cephalalgia. 2007; 27: 422-428. (Pubitemid 46632602)
126. Gupta S, Amrutkar DV, Mataji A, et al,. Evidence for CGRP re-uptake in rat dura mater encephali. Br J Pharmacol. 2010; 161: 1885-1898.
127. Strecker T, Messlinger K,. [Neuropeptide release in the dura mater encephali in response to nitric oxide-relevance for the development of vascular headaches?] Schmerz. 2003; 17: 179-184. (Pubitemid 36781450)
128. Eltorp CT, Jansen-Olesen I, Hansen AJ,. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia. 2000; 20: 838-844. (Pubitemid 32154566)
129. Goadsby PJ, Edvinsson L, Ekman R,. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988; 23: 193-196. (Pubitemid 18081459)
130. Goadsby PJ, Edvinsson L, Ekman R,. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990; 28: 183-187. (Pubitemid 20244522)
131. Gallai V, Sarchielli P, Floridi A, et al,. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15: 384-390.
132. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J,. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000; 86: 133-138. (Pubitemid 30211712)
133. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K,. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007; 128: 209-214. (Pubitemid 46367415)
134. Bellamy JL, Cady RK, Durham PL,. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache. 2006; 46: 24-33.
135. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL,. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009; 49: 1258-1266.
136. Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J,. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia. 1994; 14: 47-54. (Pubitemid 24109971)
137. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J,. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005; 58: 561-568. (Pubitemid 41377219)
138. Gupta R, Ahmed T, Banerjee B, Bhatia M,. Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period. J Headache Pain. 2009; 10: 161-166.
139. Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J,. Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia. 2004; 24: 547-553. (Pubitemid 39272955)
140. Kruuse C, Iversen HK, Jansen-Olesen I, Edvinsson L, Olesen J,. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia. 2009; 30: 467-474.
141. Tfelt-Hansen P, Le H,. Calcitonin gene-related peptide in blood: Is it increased in the external jugular vein during migraine and cluster headache? A review. J Headache Pain. 2009; 10: 137-143.
142. Ho TW, Mannix LK, Fan X, et al,. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312. (Pubitemid 351550355)
143. Olesen J, Diener HC, Husstedt IW, et al,. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110. (Pubitemid 38298990)
144. Petersen KA, Birk S, Lassen LH, et al,. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147. (Pubitemid 40193957)
145. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J,. BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005; 77: 202-213. (Pubitemid 40269135)
146. Sinclair SR, Kane SA, Van der Schueren BJ, et al,. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol. 2010; 69: 15-22.
147. Ho TW, Edvinsson L, Goadsby PJ,. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6: 573-582.
148. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J,. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol. 2004; 143: 697-704. (Pubitemid 39611605)
149. Sur C, Hargreaves R, Bell I, et al,. CSF levels and binding pattern of
150. Connor KM, Shapiro RE, Diener HC, et al,. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.
151. Ho TW, Ferrari MD, Dodick DW, et al,. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
152. Edvinsson L, Ho TW,. CGRP receptor antagonism and migraine. Neurother. 2010; 7: 164-175.
153. Bredt DS,. Endogenous nitric oxide synthesis: Biological functions and pathophysiology. Free Radic Res. 1999; 31: 577-596.
154. Marsh N, Marsh A,. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000; 27: 313-319. (Pubitemid 30194171)
155. Olesen J, Thomsen LL, Iversen HK,. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994; 15: 149-153. (Pubitemid 24156497)
156. Buzzi MG, Moskowitz MA,. The pathophysiology of migraine: Year 2005. J Headache Pain. 2005; 6: 105-111. (Pubitemid 40916524)
157. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J,. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999; 19: 660-667. (Pubitemid 29465917)
158. Iversen HK, Olesen J,. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996; 16: 412-418. (Pubitemid 26338471)
159. Tfelt-Hansen P, Daugaard D, Lassen LH, Iversen HK, Olesen J,. Prednisolone reduces nitric oxide-induced migraine. Eur J Neurol. 2009; 16: 1106-1111.
160. Thomaides T, Karapanayiotides T, Kerezoudi E, et al,. Intravenous valproate aborts glyceryl trinitrate-induced migraine attacks: A clinical and quantitative EEG study. Cephalalgia. 2008; 28: 250-256. (Pubitemid 351172035)
161. Olesen J,. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008; 120: 157-171.
162. Gozalov A, Jansen-Olesen I, Klaerke D, Olesen J,. Role of BK(Ca) channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat. Cephalalgia. 2007; 27: 1120-1127. (Pubitemid 47476138)
163. Akerman S, Williamson DJ, Kaube H, Goadsby PJ,. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol. 2002; 452: 223-228. (Pubitemid 35283934)
164. Strecker T, Dux M, Messlinger K,. Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J Vasc Res. 2002; 39: 489-496. (Pubitemid 36091839)
165. Johnson KW, Nelson DL, Dieckman DK, et al,. Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation. Cephalalgia. 2003; 23: 117-123. (Pubitemid 36356832)
166. Messlinger K, Suzuki A, Pawlak M, Zehnter A, Schmidt RF,. Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br J Pharmacol. 2000; 129: 1397-1404. (Pubitemid 30175712)
167. Akerman S, Williamson DJ, Kaube H, Goadsby PJ,. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002; 137: 62-68. (Pubitemid 34983464)
168. DeCol R, Koulchitsky SV, Messlinger KB,. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. Neuroreport. 2003; 14: 229-232. (Pubitemid 36308416)
169. Lin Q, Palecek J, Paleckova V, et al,. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol. 1999; 81: 1075-1085. (Pubitemid 29272425)
170. Luo ZD, Cizkova D,. The role of nitric oxide in nociception. Curr Rev Pain. 2000; 4: 459-466.
171. Costa A, Smeraldi A, Tassorelli C, Greco R, Nappi G,. Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. Neurosci Lett. 2005; 383: 7-11. (Pubitemid 40779946)
172. Coderre TJ, Yashpal K,. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci. 1994; 6: 1328-1334. (Pubitemid 24243638)
173. Mao J, Price DD, Zhu J, Lu J, Mayer DJ,. The inhibition of nitric oxide-activated poly(ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat. Pain. 1997; 72: 355-366. (Pubitemid 27390734)
174. Read SJ, Parsons AA,. Sumatriptan modifies cortical free radical release during cortical spreading depression. A novel antimigraine action for sumatriptan? Brain Res. 2000; 870: 44-53. (Pubitemid 30408402)
175. Caggiano AO, Kraig RP,. Neuronal nitric oxide synthase expression is induced in neocortical astrocytes after spreading depression. J Cereb Blood Flow Metab. 1998; 18: 75-87. (Pubitemid 28019014)
176. Shen PJ, Gundlach AL,. Prolonged induction of neuronal NOS expression and activity following cortical spreading depression (SD): Implications for SD- and NO-mediated neuroprotection. Exp Neurol. 1999; 160: 317-332.
177. Schytz HW, Schoonman GG, Ashina M,. What have we learnt from triggering migraine? Curr Opin Neurol. 2010; 23: 259-265.
178. Luthringer R, Djupesland PG, Sheldrake CD, et al,. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol. 2009; 61: 1219-1228.
179. Tvedskov J, Tfelt-Hansen P, Petersen K, Jensen L, Olesen J,. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. Cephalalgia. 2010; 30: 1346-1353.
180. Vernieri F, Moro L, Altamura C, et al, Antonelli Inc. Patients with migraine with aura have increased flow mediated dilation. BMC Neurol. 2010; 10: 18.
181. Vernieri F, Tibuzzi F, Pasqualetti P, et al,. Increased cerebral vasomotor reactivity in migraine with aura: An autoregulation disorder? A transcranial Doppler and near-infrared spectroscopy study. Cephalalgia. 2008; 28: 689-695. (Pubitemid 351799749)
182. DiClemente L, Coppola G, Magis D, et al,. Nitroglycerin sensitises in healthy subjects CNS structures involved in migraine pathophysiology: Evidence from a study of nociceptive blink reflexes and visual evoked potentials. Pain. 2009; 144: 156-161.
183. Lea RA, Curtain RP, Shepherd AG, Brimage PJ, Griffiths LR,. No evidence for involvement of the human inducible nitric oxide synthase (iNOS) gene in susceptibility to typical migraine. Am J Med Genet. 2001; 105: 110-113.
184. Borroni B, Rao R, Liberini P, et al,. Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura. Headache. 2006; 46: 1575-1579. (Pubitemid 44722196)
185. Toriello M, Oterino A, Pascual J, et al,. Lack of association of endothelial nitric oxide synthase polymorphisms and migraine. Headache. 2008; 48: 1115-1119. (Pubitemid 351952086)
186. Gruber HJ, Bernecker C, Lechner A, et al,. Increased nitric oxide stress is associated with migraine. Cephalalgia. 2010; 30: 486-492.
187. Schurks M, Kurth T, Buring JE, Zee RY,. A candidate gene association study of 77 polymorphisms in migraine. J Pain. 2009; 10: 759-766.
188. Griffiths LR, Nyholt DR, Curtain RP, Goadsby PJ, Brimage PJ,. Migraine association and linkage studies of an endothelial nitric oxide synthase (NOS3) gene polymorphism. Neurology. 1997; 49: 614-617. (Pubitemid 27368915)
189. Johnson MP, Lea RA, Colson NJ, Macmillan JC, Griffiths LR,. A population genomics overview of the neuronal nitric oxide synthase (nNOS) gene and its relationship to migraine susceptibility. Cell Mol Biol. 2005; 51: 285-292. (Pubitemid 43093380)
190. Sjostrand C, Modin H, Masterman T, Ekbom K, Waldenlind E, Hillert J,. Analysis of nitric oxide synthase genes in cluster headache. Cephalalgia. 2002; 22: 758-764. (Pubitemid 36606056)
191. Hansen JM, Thomsen LL, Olesen J, Ashina M,. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia. 2008; 28: 496-505. (Pubitemid 351502557)
192. Hansen JM, Thomsen LL, Marconi R, Casari G, Olesen J, Ashina M,. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia. 2008; 28: 367-375. (Pubitemid 351341452)
193. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J,. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003; 23: 877-886. (Pubitemid 37352624)
194. Lassen LH, Ashina M, Christiansen I, et al,. Nitric oxide synthase inhibition: A new principle in the treatment of migraine attacks. Cephalalgia. 1998; 18: 27-32. (Pubitemid 28096515)
195. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J,. Nitric oxide synthase inhibition in migraine. Lancet. 1997; 349: 401-402. (Pubitemid 27077677)
196. Van der Schueren BJ, Lunnon MW, Laurijssens BE, et al,. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol. 2009; 49: 281-290.
197. Ebright GE,. The effects of nitroglycerin on those engaged in its manufacture. JAMA. 1914; 4: 201-202.
198. Christiansen I, Iversen HK, Olesen J, Tfelt-Hansen P,. Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. J Headache Pain. 2008; 9: 215-220.
199. Weaber C,. Serotonin and other biogenic amines. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd edn. Philadelphia, PA: Lippincott Williams and Wilkins; 2006: 143-149.
200. Ishikawa S, Sperelakis N,. A novel class (H3) of histamine receptors on perivascular nerve terminals. Nature. 1987; 327: 158-160. (Pubitemid 17062761)
201. Krabbe AA, Olesen J,. Headache provocation by continuous intravenous infusion of histamine, clinical results and receptor mechanisms. Pain. 1980; 8: 253-259. (Pubitemid 10149305)
202. Toda N, Okamura T,. Mechanism underlying the response to vasodilator nerve stimulation in isolated dog and monkey cerebral arteries. Am J Physiol. 1990; 259 (Pt 2): H1511-H1517.
203. Ayajiki K, Okamura T, Toda N,. Involvement of nitric oxide in endothelium-dependent, phasic relaxation caused by histamine in monkey cerebral arteries. Jpn J Pharmacol. 1992; 60: 357-362. (Pubitemid 23068784)
204. Akerman S, Williamson DJ, Kaube H, Goadsby PJ,. The role of histamine in dural vessel dilation. Brain Res. 2002; 956: 96-102. (Pubitemid 35335561)
205. Lassen LH, Thomsen LL, Olesen J,. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport. 1995; 6: 1475-1479.
206. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J,. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. Eur J Clin Pharmacol. 1996; 49: 335-339.
207. Schmetterer L, Wolzt M, Graselli U, et al,. Nitric oxide synthase inhibition in the histamine headache model. Cephalalgia. 1997; 17: 175-182. (Pubitemid 27257342)
208. Garcia-Martin E, Martinez C, Serrador M, et al,. Histamine-N-methyl transferase polymorphism and risk for migraine. Headache. 2008; 48: 1343-1348.
209. Millan-Guerrero RO, Cardenas MA, Ocampo AA, Pacheco MF,. Histamine as a therapeutic alternative in migraine prophylaxis: A randomized, placebo-controlled, double-blind study. Headache. 1999; 39: 576-580. (Pubitemid 29496020)
210. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al,. Subcutaneous histamine versus topiramate in migraine prophylaxis: A double-blind study. Eur J Neurol. 2008; 59: 237-242. (Pubitemid 351561092)
211. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al,. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: A randomized, controlled, double-blind study. Eur J Neurol. 2007; 14: 1079-1084. (Pubitemid 47459724)
212. Millan-Guerrero RO, Isais-Millan S, Barreto-Vizcaino S, Rivera-Castano L, Rios-Madariaga C,. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: A randomized, double-blind study. Eur J Neurol. 2009; 16: 88-94.
213. Pietrini U, deLuca M, delBene E, et al,. Prophylactic activity of increasing doses of intravenous histamine in refractory migraine: Retrospective observations of a series of patients with migraine without aura. Curr Ther Res. 2004; 65: 70-78. (Pubitemid 38953434)
214. Millan-Guerrero RO, Isais-Millan R, Benjamin TH, Tene CE,. Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: Phase III study. Can J Neurol Sci. 2006; 33: 195-199. (Pubitemid 43845173)
215. Freitag FG, Diamond S, Bambhvani S,. IV histamine in chronic cluster headaches. Cephalalgia. 1997; 61: 141. (Pubitemid 127791267)
216. Diamond S, Freitag FG, Bambhvani S,. IV histamine desensitization therapy and recidivism: Chronic cluster headache patients. Cephalalgia. 1997; 17: 457.
217. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C,. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985; 58: 213-217. (Pubitemid 15017193)
218. Wolff HG,. Headache and cranial arteries. Tr A Am Physicians. 1938; 53: 193.
219. Saxena PR, Maassen VA, Heiligers JP, Scalbert E, Lemaitre BG,. Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery. Pharmacol Toxicol. 1996; 79: 199-204. (Pubitemid 26338725)
220. Macintyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS,. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993; 87: 401-405. (Pubitemid 23040908)
221. Saxena PR,. Selective carotid vasoconstriction by ergotamine as a relevant mechanism in its antimigraine action. Arch Neurobiol (Madr). 1974; 37 (Suppl.): 301-315.
222. Saxena PR, Forsyth RP, Johnston BM, De Werk A,. Regional and systemic haemodynamic changes evoked by 5-hydroxytryptamine in awake and anaesthetized rabbits. Eur J Pharmacol. 1978; 50: 61-68.
223. Saxena PR, Verdouw PD,. Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol. 1982; 332: 501-520. (Pubitemid 13253467)
224. Heyck H,. Pathogenesis of migraine. Res Clin Stud Headache. 1969; 2: 1-28.
225. Bures J, Buresova O, Krivanek J,. The Mecahnism and Applications of Leaos Spreading Depression of Electroencephalaographic Activity. Prague: Academic Press Inc.; 1974.
226. Lashley K,. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry. 1941; 46: 331-339.
227. Milner PM,. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. Electroencephalogr Clin Neurophysiol. 1959; 10: 1105-1110.
228. Markowitz S, Saito K, Moskowitz MA,. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci. 1987; 7: 4129-4136. (Pubitemid 18012423)
229. Moskowitz MA, Reinhard JF Jr, Romero J, Melamed E, Pettibone DJ,. Neurotransmitters and the fifth cranial nerve: Is there a relation to the headache phase of migraine? Lancet. 1979; 2: 883-885.
230. Moskowitz MA,. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43 (Suppl. 3): S16-S20.
231. Feindel W, Penfield W, Mcnaughton F,. The tentorial nerves and Iocalization of intracranial pain in man. Neurology. 1960; 10: 555-563.
232. Tassorelli C, Joseph SA,. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res. 1995; 682: 167-181.
233. Nakajima T, Daval JL, Gleiter CH, Deckert J, Post RM, Marangos PJ,. C-fos mRNA expression following electrical-induced seizure and acute nociceptive stress in mouse brain. Epilepsy Res. 1989; 4: 156-159. (Pubitemid 19224531)
234. Ebersberger A, Averbeck B, Messlinger K, Reeh PW,. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience. 1999; 89: 901-907. (Pubitemid 29071014)